Concepedia

Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models

Robert Cavanagh, Patricia Monteiro, Cara Moloney, Alessandra Travanut, Fatemeh Mehradnia, Vincenzo Taresco, Ruman Rahman, Stewart G. Martin, Anna M. Grabowska, Marianne Ashford,

Biomaterials Science · 2024 · 12 citations · 55 references

DOIFull text

Open access

Concepts

Abstract

Combinations of the topoisomerase II inhibitor doxorubicin and the poly (ADP-ribose) polymerase inhibitor olaparib offer potential drug–drug synergy for treatment of triple negative breast cancers (TNBC) both in free drug form and when delivered by oxidation-responsive nanoparticles.

References

55

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

Ting‐Chao Chou · Cancer Research · 2010 · 5.7K citations

, , +15

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

, , +16

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Junko Murai, Shar-yin N. Huang, Benu Brata Das et al. · Cancer Research · 2012 · 2.2K citations · Full text

, , +17

Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

Katrina Bauer, Monica Brown, Rosemary D. Cress et al. · Cancer · 2007 · 2.1K citations

, , +11

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

Xiaofeng Zheng, Julienne L. Carstens, Jiha Kim et al. · Nature · 2015 · 2K citations · Full text

, , +16